ISSN: 2455-5282
Global Journal of Medical and Clinical Short Communications
Short Communication       Open Access      Peer-Reviewed

The case of acute psychotic episode treatment in patient with myasthenia gravis

Patrycja Pajor*, Maria Jankowska and Marek Jarema

Department of Psychiatry, Institute of Psychiatry & Neurology, Warsaw, Poland
*Corresponding author: Patrycja Pajor, Department of Psychiatry, Institute of Psychiatry & Neurology, Warsaw, Poland, Tel: +48 667740999; E-mail: ppajor@ipin.edu.pl, patrycja.pajor@wp.pl
Received: 28 May, 2021 |Accepted: 08 June, 2021 | Published: 09 June, 2021
Keywords: Myasthenia gravis; Uveitis; Antipsychotic treatment

Cite this as

: Pajor P, Jankowska M, Jarema M (2021) The case of acute psychotic episode treatment in patient with myasthenia gravis. Glob J Medical Clin Case Rep 8(2): 063-064. DOI: 10.17352/2455-5282.000130

A seventy-one old male patient with no previous Hx of mental disorders including alcohol use and with no family Hx of mental disorders was admitted to psychiatric ward due to acute aggression, agitation, excessive irritability and lack olf sleep. He suferred from myasthenia gravis for years and was treated chronically with ambenonium 20 mg daily. Because of comorbidity of uveitis with macular edema he received treatment with prednisolone 70mg daily. Because of acute psychotic symptoms the treatment with olanzapine up to 20mg/d was introduced without effect. The treatment was switched to haloperidol 10mg/d with gradual improvement of patient’s behaviour. He was discharged from the hospital with indication to continue psychiatric, ohpthalomogic, and neurological outpatient care.

Case report

A 71-year-old patient, with no medical history of psychiatrical treatment, was admitted to the hospital because of psychomotor agitation, irritability, decreased need for sleep and aggression. The onset of the symptoms had been observed approximatelly one month before hospital admission, symptoms gradually worsened with time. Patient was brought to the hospital by the police, immobilized and handcuffted due to destructive, disorganized behaviour. According to his family for years he has been irritable and nervous, periodically abusing alcohol.

This patient has been suffering from myasthenia gravis with a mild clinical course for 6 years and was treated chronically with ambenonium 20 mg per day, currently with no neurological symptoms. Patient also had a history of uveitis with macular edema. For ophthalmic reasons, 6 months ago treatment with oral corticosteroids was initiated, starting with a dose of 70 mg/d prednisolone, in decreasing weekly doses. The treatment was temporarily discontinued due to SARS-CoV-2 infection. Taking the above-mentioned drugs by the patient resulted in psychomotor agitation, insomnia and irritability. Despite these symptoms, the therapy was recontinued three months ago: corticosteroids at a dose of 50 mg/d predniosolone were restarted, in a similar scheme; recently with the dose of 17,5mg per day methotrexate 20 mg once a week was added to the treatment.

During the initial psychiatric consultation in the emergency room patient was uncooperative, actively negativistic, psychomotor agitated, aggressive towards the personel. The patient was admitted mandatory to a psychiatric ward. On admission the patient was comprehensively oriented, in difficult contact, negativistic, did not answer questions, irritable, meticulous in his statements. He showed vivid affect, accelerated thinking, elevated mood, expressed delusions, denied suicidal thoughts. In laboratory tests, slight leukocytosis, neutropenia, increased transaminases were shown. Physical examination did not show any abnormalities.

Patient was diagnosed with acute psychotic disorder due to known physiological condition [ICVD-10: F06.3]. Other possible mental disorders such as Brief Psychotic D/O, Bipolar Mania, Psychosis NOS were excluded in the basis of fact that the symptoms have started after the use of medications for uveitis (corticosteroids). This was the main reason that other psychiatric diagnoses have been excluded. At the beginning sedatives were not given because of the history of myasthenia gravis. Due to the lack of cooperation, considerable agitation, delusional thinking, active aggression towards the staff and the need for repeated use of restraint, olanzapine 10 mg/day i.m. was administered. The treatment was well tolerated so the dose was increased to 20 mg/d i.m with the addition of hydroxyzine PRN. No adverse effects and no deterioration of the neurological status were observed. After 7 days of treatment, the patient was still disorganized, maladjusted, vulgar, he uttered delusional content. Due to the lack of improvement, olanzapine was discontinued and haloperidol at a dose of 10 mg/d i.m. was started. Tretment was well tolerated. After 7 days of haloperidol treatment patient's condition gradually improved, mood was balanced, the patient became critical of the spoken delusional content, but still remained large, periodically coprolal. When patent's state became more stabile the noncontrast CT scan of the brain was obtained with no abnormalities shown. The form of treatment was changed to oral haloperidol at a dose of 10 mg/day, after 6 days the patient was discharged home in a state of improvement, with reccomentadion of continuing treatment in an outpatient setting.

Discussion

Myasthenia gravis is an autoimmune neuromuscular disease in which antibodies against the acetylcholine receptor are produced. The severity of symptoms ranges from mild eye symptoms, the weakness and fatigue of various muscle groups to the life-threatening condition of myasthenic crisis. In some patients with myasthenia gravis, muscle weakness is limited to the muscles of the eyeball [1]. Patients with this type of myasthenia gravis are at risk of developing generalized disease especially in the early stages of the disease. Ninety percent of people who have had the ocular form for more than 2 years will remain in this subgroup [2]. Observational studies [3] suggest that prednisolone treatment reduces the risk of developing generalized myasthenia gravis [4]. Patients with myasthenia gravis often respond well to low doses (10–30 mg every other day) of corticosteroids alone [5]. Although the neuropsychiatric symptoms associated with the use of high doses of corticosteroids (defined as greater than 40 mg of prednisone or its equivalent) are often complex and unpredictable, they may be used within the first weeks of steroid treatment [6]. It is estimated that about 20% of patients receiving treatment may develop a psychiatric disorder such as mania, psychosis or depression [7]. Manic episodes are the most frequent manifestations of a corticosteroid-induced neuropsychiatric disorder. The literature suggests that patients treated for steroid-induced mania are more likely to present severe psychotic symptoms than patients who have mania not induced by substances. Persecutory delusions, auditory hallucinations, and disorganized behavior are the dominant symptoms among this group of patients [4,8,9]. It should be underlined that many medications can worsen the symptoms of myasthenia gravis, including antipsychotics, antidepressants, sedatives. Antipsychotic drugs carry a low risk of worsening myasthenia gravissymptoms in comparison with medicines from other groups [10]. Antipsychotics with affinity for muscarinic cholinergic receptors, such as olanzapine, quetiapine, clozapine, should be used with caution. The use of olanzapine for this patient was justified by the known sedative properties of this drug (along with antipsychotic activity) and this drugi is concidered as first-choice medication for aggresive psychotic patients. The classic antipsychotics such as haloperidol, amisulpride or paliperidone were described as safer [11] which is confirmed by our case report.

Conclusion

Regardless of the fact that sedative medications are contraindicated in patients with myasthenia gravis, in some conditions there is the need to treat patients with antipsychotics. This case indicates that antipsychotic treatment administered due to psychotic episode with severe aggresive behaviour - constituting in immediate harm to oneself and others - to a patient suffering from myasthenia gravis, may result in beneficial effect without side effects and without worsening of myasthenia symptoms. We present this report to underline that regard the limitation of antipsychotic use in patients suffering frrom both myasthenia gravis and uveitis, the use of a classic antipsychotic instead of atypical antipsychotic drug which proved to be uneffective was sucessful.

  1. Albores‐Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, et al. (2010) Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population based study. J Cutan Pathol 37: 20-27. Link: https://bit.ly/3wTiRRf
  2. Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, et al. (2014) Response rate and durability of chemotherapy for metastatic Merkel cell carcinoma among 62 patients. American Society of Clinical Oncology 32. Link: https://bit.ly/2RjUSeU
  3. Tai PT, Yu E, Winquist E, Hammond A, Stitt L, et al. (2000) Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol 18: 2493-2499. Link: https://bit.ly/3pe9FUM
  4. Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, et al. (2011) Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res 17: 6671-6680. Link: https://bit.ly/3uMKPMQ
  5. Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, et al. (2013) Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res 19: 5351-5360. Link: https://bit.ly/3vQ9fXa
  6. Paulson KG, Carter JJ, Johnson LG , Cahill KW , Iyer JG ,et al. (2010) Antibodies to merkel cell polyomavirus T antigen oncoproteins reflect tumor burden in merkel cell carcinoma patients. Cancer Res 70: 388-8397. Link: https://bit.ly/2RhSqpf
  7. Goh G, Walradt T, Markarov V, Blom A, Riaz N, et al. (2016) Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget 7: 3403. Link: https://bit.ly/3phwirB
  8. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, et al. (2013) PD-L1 expression in the merkel cell carcinoma microenvironment: association with inflammation, merkel cell polyomavirus, and overall survival. Cancer Immunol Res 1: 54-63. Link: https://bit.ly/3ikZ7Si
  9. Terheyden P, Becker JC (2017) New developments in the biology and the treatment of metastatic Merkel cell carcinoma. Curr Opin Oncol 29: 221-226. Link: https://bit.ly/3pe7NLZ
  10. Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, et al. (2016) PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med 374: 2542-2552. Link: https://bit.ly/3cduD14
  11. Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, et al. (2016) Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncology 17: 1374-1385. Link: https://bit.ly/3pi35fX
  12. Lebbe C, Becker JC, Grob JJ, Malvehy J, Del Marmol V, et al. (2015) Diagnosis and treatment of Merkel cell carcinoma. European consensus-based interdisciplinary guideline. Eur J Cancer 51: 2396-2403. Link: https://bit.ly/3iih7wL
  13. Lemos BD, Storer BE, Iyer JG , Phillips JL, Bichakjian CK, et al. (2010) Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol 63: 751-761. Link: https://bit.ly/34HaWub
  14. What does Cancer Genome Interpreter do?. Link: https://bit.ly/3wU3aJG
  15. Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, et al. (2013) Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Med 2: 76-85. Link: https://bit.ly/3wShSAD
  16. Ajithkumar T, Parkinson C, Fife K, Corrie P, Jefferies S, et al. (2015) Evolving treatment options for melanoma brain metastases. Lancet Oncol 16: e486-e497. Link: https://bit.ly/3g9MzLb
  17. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, et al. (2015) Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen. Cancer Immunol Res 3: 345-355. Link: https://bit.ly/2RXIykZ
©2021 Pajor P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.